The adjournment is to allow for the solicitation of additional votes in favor of the proposal contained in the definitive proxy statement that Mateon filed with the
The special meeting will reconvene at
During the period of the adjournment, Mateon will continue to solicit proxies from its stockholders. Stockholders who have not already done so are encouraged to vote - because passage of the proposal requires a majority of outstanding shares to vote in favor, unvoted shares have the same effect as shares voted against. Stockholders who have already voted do not need to recast their votes unless they wish to change their votes. Proxies previously submitted for the meeting will be voted as previously instructed at the reconvened meeting unless properly revoked.
Both leading independent proxy advisory firms -
Today's adjournment provides stockholders who have not yet voted an additional opportunity to do so. All stockholders are reminded that every vote will count. Stockholders who need assistance in voting their shares or who have questions are encouraged to contact Mateon's proxy solicitor, Morrow Sodali - brokers call collect: (203) 658‐9400, stockholders call toll free: (800) 662-5200.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACTS Investors: firstname.lastname@example.org 650-635-7000 Media:
JPA Health Communications Nic DiBellanic@jpa.com 617-945-5183
News Provided by Acquire Media